|
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that it has
launched a multi-center Phase 2 study evaluating the use of Ceflatonin(R)
(homoharringtonine or HHT) in combination with Gleevec(R) (imatinib mesylate),
in patients with chronic myelogenous leukemia (CML) who have developed
resistance to Gleevec(R). Dr. Jorge Cortes, Professor of Leukemia at the M.D.
Anderson Cancer Center in Houston, Texas, is the principal investigator for the
study.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
